Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

571 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia.
Gagelmann N, Bogdanov R, Stölzel F, Rautenberg C, Panagiota V, Becker H, Radujkovic A, Luft T, Christopeit M, Finke J, Platzbecker U, Ditschkowski M, Schroeder T, Koldehoff M, Heuser M, Kobbe G, Beelen DW, Germing U, Kröger N. Gagelmann N, et al. Among authors: platzbecker u. Transplant Cell Ther. 2021 Jan;27(1):95.e1-95.e4. doi: 10.1016/j.bbmt.2020.10.007. Epub 2020 Oct 9. Transplant Cell Ther. 2021. PMID: 33039516 Free article.
Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission.
Strodtbeck D, Bornhäuser M, Hänel M, Lerche L, Schaich M, Illmer T, Thiede C, Geissler G, Herbst R, Ehninger G, Platzbecker U. Strodtbeck D, et al. Among authors: platzbecker u. Bone Marrow Transplant. 2005 Dec;36(12):1083-8. doi: 10.1038/sj.bmt.1705176. Bone Marrow Transplant. 2005. PMID: 16247435
Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia.
Platzbecker U, Thiede C, Füssel M, Geissler G, Illmer T, Mohr B, Hänel M, Mahlberg R, Krümpelmann U, Weissinger F, Schaich M, Theuser C, Ehninger G, Bornhäuser M. Platzbecker U, et al. Leukemia. 2006 Apr;20(4):707-14. doi: 10.1038/sj.leu.2404143. Leukemia. 2006. PMID: 16482208 Clinical Trial.
Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.
Bornhäuser M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, Hänel M, Schuler U, Thiede C, Kiani A, Platzbecker U, Ehninger G. Bornhäuser M, et al. Among authors: platzbecker u. Clin Cancer Res. 2008 Sep 1;14(17):5585-93. doi: 10.1158/1078-0432.CCR-08-0894. Clin Cancer Res. 2008. PMID: 18765552 Clinical Trial.
Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium.
von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhäuser M. von Bonin M, et al. Among authors: platzbecker u. Bone Marrow Transplant. 2009 Feb;43(3):245-51. doi: 10.1038/bmt.2008.316. Epub 2008 Sep 29. Bone Marrow Transplant. 2009. PMID: 18820709
571 results